Novo Nordisk stock falls as heart drug trials are halted despite pediatric obesity win
Published on 09/08/2026 at 17:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock (ISIN DK0060534915) is trading lower after the company disclosed in early September 2026 that it will discontinue two late-stage cardiovascular trials of its experimental anti-inflammatory drug ziltivekimab, even as new STEP Young data show semaglutide helping 40.4% of children aged 6 to under 12 years move out of obesity after 68 weeks.BigGo Finance The mixed clinical picture as of September 8, 2026 is forcing investors to reassess both the company’s diversification efforts beyond obesity and the durability of its core obesity growth engine.
Heart-failure trials halted, pipeline risk rises
On September 7, 2026, Novo Nordisk informed investigators that it would end the HERMES and ATHENA phase 3 studies of ziltivekimab for heart failure with inflammation after an independent data monitoring committee concluded there was a low likelihood either trial would achieve meaningful clinical benefit.BigGo Finance According to Reuters, the decision follows an earlier ZEUS phase 3 failure in July, where ziltivekimab lowered inflammatory markers but did not reduce major cardiovascular events such as deaths and heart attacks.
Market commentary on September 7, 2026 highlighted that Novo Nordisk shares around 46.60 USD in US trading fell nearly 2% after the disclosure that these two late-stage heart-failure trials would be scrapped, undercutting an otherwise promising pediatric obesity readout for semaglutide.BigGo Finance The move leaves the ARTEMIS phase 3 trial, which is testing ziltivekimab in patients recovering from heart attacks, as the main remaining late-stage study for this asset, with data expected in the first half of 2027.BigGo Finance
Pediatric STEP Young data strengthen obesity franchise
In contrast to the cardiovascular setback, Novo Nordisk reported positive results from its phase 3 STEP Young trial evaluating once-weekly semaglutide in children aged 6 to under 12 years with obesity.GuruFocus After 68 weeks of treatment, 40.4% of participants receiving semaglutide no longer met obesity criteria, compared with none in the placebo group, highlighting a substantial efficacy gap versus standard care.GuruFocus Over 85% of children in the trial entered with severe obesity, making the shift out of obesity for more than two-fifths of treated patients particularly striking.
According to an analysis summarizing Novo Nordisk’s obesity portfolio, total reported Obesity care sales in the first half of 2026 increased 20% year over year in Danish kroner, or 24% at constant exchange rates, driven by higher Wegovy sales including incremental contributions from the newly launched Wegovy pill.Zacks For investors, the STEP Young results and double-digit growth in obesity care underline how much of Novo Nordisk’s medium-term earnings trajectory now depends on expanding obesity treatment into younger age groups and new formulations.
Stock performance, valuation and analyst views
Recent market data show the US-listed Novo Nordisk American depositary shares trading at around 45.46 USD, down 2.45% intraday, with the quote captured on September 7, 2026 in early US trading.MarketBeat A separate price snapshot on September 7, 2026 indicated Novo Nordisk trading at 46.60 USD, nearly 2% lower than the prior close, reflecting investor caution after the ziltivekimab trial terminations.Yahoo Finance In Copenhagen, one recent closing price reported for the Nasdaq Copenhagen listing was 298.95 DKK, corresponding to a roughly 1.9% decline versus the preceding session as of September 7, 2026.IT BOLTWISE
Valuation analyses suggest that Novo Nordisk stock is trading well below some intrinsic-value estimates: one GF Value-based assessment cited a fair value of 105.85 USD, indicating that the stock price around 46.60 USD sits 55.98% beneath that modeled level as of September 7, 2026.Yahoo Finance Other GuruFocus reviews similarly describe the shares as more than 50% undervalued based on GF Value metrics while noting a dividend yield around 3.86% supported by a 50% payout ratio and approximately 27.8% dividend growth over three years, though the precise yield and growth figures are tied to the valuation framework used.GuruFocus
Risk focus: concentration in obesity and trial setbacks
Analyst commentary in early September 2026 emphasizes that ziltivekimab’s repeated phase 3 disappointments tighten Novo Nordisk’s concentration risk around its obesity and diabetes franchise. A note from Goldman Sachs cited by Yahoo Finance argues that, with limited clinical data to support long-term revenues from newer pipeline assets, investor focus is likely to shift toward business development plans and strategy updates at the company’s September 21, 2026 capital markets day. The analyst points out that disappointing data from bolt-on acquisitions and pipeline programs, including ocedurenone, monlunabant and ziltivekimab, have reinforced skepticism about Novo Nordisk’s track record in integrating larger deals and diversifying beyond Wegovy.
For shareholders, the immediate quantified risk is that halting two large ziltivekimab heart-failure trials removes potential future revenue streams that could have helped balance the heavy reliance on obesity care. At the same time, the STEP Young data and the 20% year-over-year growth in Obesity care sales in the first half of 2026 show the core obesity business still growing strongly in both injectable and oral formats.Zacks The tension between pipeline setbacks and obesity momentum is now a central theme in how the market prices Novo Nordisk stock.
Semaglutide and key obesity products
Semaglutide, marketed under brand names including Wegovy for obesity, is the backbone of Novo Nordisk’s current growth strategy. The STEP Young phase 3 trial adds to a body of evidence demonstrating that once-weekly semaglutide can meaningfully reduce body mass index and shift children with severe obesity below commonly used obesity thresholds over a 68-week period.GuruFocus In adult populations, Wegovy has already driven substantial revenue growth, with Obesity care sales rising 20% in the first half of 2026 and 24% at constant exchange rates as new formulations such as the Wegovy pill expand the franchise.Zacks
Stock and market context
As of the last completed trading day with detailed data, Novo Nordisk’s primary listing on Nasdaq Copenhagen closed at 298.95 DKK on September 7, 2026, with pre-market indications pointing to a roughly 1.9% decline from the previous close and mirroring an almost 2% drop in the US-traded ADR at 46.60 USD.IT BOLTWISE At these levels, the shares remain far below some cited GF Value fair-value estimates above 100 USD for the ADR, underscoring how the market is discounting both concentration risk in obesity and uncertainty around non-obesity pipeline assets.Yahoo Finance
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0060534915
- Ticker: NOVO-B
- Trading venue: Nasdaq Copenhagen
- Price (as of September 7, 2026): 298.95 DKK
- Market capitalization: 319,000,000,000 DKK (as of September 7, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: OMX Copenhagen 25
